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ABSTRACT
Objectives Pulmonary hypertension is a life- shortening 
disease that has a considerable impact on quality of 
life. Improving our understanding of how individuals are 
affected and cope with the disease will help to improve 
services and outcomes. This review synthesises the 
published qualitative research that has listened to adults 
discuss their experiences of living with the disease.
Design A comprehensive systematic search of four 
databases was conducted in May 2020: Web of Science, 
PubMed, PsycINFO and Cochrane Library. Suitable 
studies were evaluated using the Critical Appraisal Skills 
programme. Findings from the studies were extracted and 
subjected to a thematic synthesis.
Results Nineteen articles were identified reflecting 
the experiences of over 1900 individuals impacted by 
pulmonary hypertension from Europe, North and South 
America and Asia. Ten studies did not report participant’s 
WHO functional class of pulmonary hypertension, which 
resulted in comparing experiences between different 
severity difficult. All studies met the majority of the quality 
assessment items. Six descriptive themes emerged 
discussing participant’s experiences of diagnosis, 
treatment, prognosis, healthcare professionals, impact 
and coping with pulmonary hypertension. Four higher 
order analytical themes were developed from the 
descriptive themes, reflecting: (i) uncertainties and anxiety 
that participants encountered related to pulmonary 
hypertension; (ii) lack of recognition of the impact of the 
condition; (iii) frustration at the paucity of awareness of 
pulmonary hypertension in society and healthcare settings 
and (iv) participant’s accounts of transitioning through 
different stages of living with the disease.
Conclusions These findings form the first synthesis of 
experiences of life in individuals impacted by pulmonary 
hypertension and illustrate the multifaceted impact of the 
condition. The voices of numerous groups are missing 
from the literature highlighting the need for additional 
research. The results have implications for clinical practice 
emphasising the role of educational and psychological 
therapies to support those with the disease.
INTRODUCTION
Pulmonary hypertension (PH) describes a 
group of conditions characterised by elevated 
pulmonary artery pressure, which untreated 
results in right heart failure and premature 
death. Five groups each sharing clinical and 
pathophysiological features can be described: 
group 1: pulmonary arterial hypertension 
(PAH); group 2: PH due to left heart disease; 
group 3: PH due to lung disease or hypoxia; 
group 4: chronic thromboembolic PH and 
group 5: PH due to unclear or miscellaneous 
disorders.1 2 The WHO functional classifica-
tion system in PH is an important tool used to 
reflect disease severity, and monitor progres-
sion of the disease and response to treat-
ment. This index ranges from I, suggestive of 
patients experiencing no or minimal symp-
toms during physical activity, to IV indicative 
of patients experiencing severe symptoms at 
rest.2
Despite improved outcomes in PH- related 
mortality associated with advancements 
in medical therapies,3–5 it remains, a life- 
shortening condition with significant physical 
and psychological morbidity and a profound 
impact on quality of life (QoL).4 Recent 
research has explored patient’s experiences 
of living with the disease,6 7 demonstrating 
the importance of psychosocial factors in 
PH on QoL8–10 and engagement in care.11 
A greater understanding of how individuals 
are affected and cope with PH should help 
to improve treatment pathways and patient- 
reported outcomes.7
Strengths and limitations of this study
 ► This is the first systematic review of the impact of 
pulmonary hypertension on adults’ experiences of 
living.
 ► A thematic synthesis approach was used, a key aim 
of which is to help inform future interventions, policy 
and clinical practice.
 ► A comprehensive search strategy was undertak-
en screening 9362 articles from four electronic 
databases.
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This review systemically synthesises the published qual-
itative evidence examining adults’ experiences of PH. 
The majority of researchers in this area have employed 
quantitative methodologies.7 These studies have investi-
gated a specific difficulty asking individuals to answer a 
series of structured questions by endorsing predefined 
responses.12–14 While this has produced large general-
isable datasets, participants may not have been able to 
discuss experiences most important to them. Qualitative 
methods, however, allow participants to describe their 
experiences, in their own words, meaning rich and fine- 
grained data can be collected. The objective of this review 
was to provide a more in- depth and nuanced under-
standing of experiences, highlight unmet needs and iden-
tify new areas of investigation.15 For instance, the current 
findings were used to help guide the development of a 
self- help intervention for anxiety in PH.
METHODS
Search strategy
This systematic review has been conducted in accordance 
with Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses and Enhancing Transparency in Reporting 
the Synthesis of Qualitative Research (ENTREQ)16 
(online supplemental 1 and 2). A comprehensive search 
of four databases was performed in January 2020, which 
was repeated in May 2020 prior to submission: Web of 
Science, PubMed, PsycINFO and Cochrane Library. The 
references of suitable articles were searched for relevant 
studies: this helped to identify one additional article17 
(tables 1 and 2). Search terms were informed by author’s 
experience of previously published articles on PH. We 
used the term ‘pulmonary hypertension’ to remain inclu-
sive as this is likely to also identify other groups of PH. 
Keywords of several suitable articles were checked to 
confirm salient words had not been omitted.
Quality assessment
Relevant studies were evaluated using the 10- item Critical 
Appraisal Skills Programme for qualitative research.18 An 
overall score was given to each article demonstrating that 
the study had achieved the majority or all (++), most (+) 
or few (−) of the criteria. The lead author (GHR) assessed 
all articles. A second researcher (CG) independently 
re- assessed approximately one- quarter of the papers 
(n=5) chosen as random. Following discussion, a 92% 
level of agreement per study was observed for all 11 items 
(including the overall score) per study, compared with an 
87% level of agreement prior to discussion. All findings, 
regardless of quality, were included in the synthesis to 
remain inclusive.
Data analysis
A thematic synthesis was adopted using four stages19:
1. GHR read each paper before extracting relevant 
information.
Table 1 Search terms
Concept 1 AND Concept 2
Pulmonary 
hypertension 
OR Pulmonary 
arterial 
hypertension
Qualitative OR thematic 
OR mixed*methods OR 
experience* OR perspective* OR 
semi*structured OR interview OR 
phenomenolog*
Table 2 Inclusion and exclusion criteria—based on the spider tool61
Inclusion Exclusion
Sample Adults (18 years or older) diagnosed with PH; participants 
who self- reported being impacted by a diagnosis of PH. 
We assumed participants were adults unless otherwise 
stated.
Children (aged <18 years), individuals without a 
diagnosis of PH.
Phenomenon of 
interest
Exploring individual’s experiences of PH, that is, 
diagnosis, treatment, psychosocial impact.
Exploring other cardiovascular conditions. 
Using qualitative methodology to address a 
quantitative research goal, that is, development 
of a quantitative clinical measure.
Design Any study that reported utilising a qualitative research 
methodology that is, open- ended question (sometimes 
known as Big ‘Q’) was considered. If participants with PH 
were grouped with individuals with a different diagnosis, 
their unique contribution must be made explicit.
Solely quantitative research methodologies 
or converted experiences to numbers, that 
is, standardised psychometric measures. 
Participants with PH grouped with other 
individuals without PH and it is not clear from 
whom data were collected from.
Evaluation Any form of qualitative analysis that aim to report on 
subjective experiences, that is, thematic analysis, 
interpretative phenomenological analysis.
Solely quantitative analysis.
Research type Published in English in a scientific journal and peer 
reviewed. No date restrictions were applied.
Grey literature, that is, books, abstracts, blogs, 
unpublished studies, reviews.
PH, pulmonary hypertension.
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2. Findings were iteratively coded by GHR with the aim of 
developing descriptive themes. Themes were informed 
by frequency and saliency of codes, as opposed to study 
characteristics (ie, sample size).
3. Analytical themes were developed, which aimed to 
go beyond the original data and descriptive themes 
in context of the review’s objective. Themes were dis-
cussed among other members of the research team.
4. Final report was written, and suitable quotations were 
selected. “ ” have been used when reporting partici-
pants’ words and ‘ ’ for authors.
Patient public involvement
There was no patient and public involvement in this 
systematic review.
RESULTS
Findings of search
Overall, 19 studies were included in the synthesis 
(figure 1). Studies were published between 2005 and 2020; 
however, 18/19 were published in the last 10 years.20 Data 
reflect over 1900 individuals across Europe, North and 
South America and Asia. Ages ranged from 19 to 91 years. 
In all but one study, the samples were predominantly 
female21—likely reflecting the gender bias observed 
in PH.22 Only three studies provided sufficient detail 
regarding sample ethnicity.17 23 24 Participants had been 
diagnosed with PH ranging from <1 year to 24 years. Ten 
studies failed to report medical information concerning 
participant’s functional class—this is important given 
that experiences seemed to differ depending on disease- 
specific issues.17 25 The majority (n=14) of studies used 
research interviews for data collection, whereas greater 
variation of analytical methods was used (table 3).
Quality assessment
All studies met the majority of the 10 quality assessment 
items (table 4). Seven studies failed to justify their decision 
for using a qualitative approach and one study provided a 
limited description of their data analysis method. Surpris-
ingly, 15 articles did not report their method of reflexivity.
Descriptive themes
Six descriptive themes emerged:
Diagnosis
Participants reported experiencing PH- related symp-
toms a “long” time [27, p. E19] prior to obtaining a diag-
nosis.21 26 27 This period was characterised by a decline 
in physical functioning, QoL and emotional and social 
difficulties.20 25 28 29 During this time, and thereafter, indi-
viduals expressed confusion over the cause of their expe-
riences28—worries that were not necessarily reduced by 
the diagnosis, which was described as having posed “more 
questions than it answers”[22, p. 3]. Participants tended to 
avoid, adapt to or explain away their symptoms: “[I] just 
assumed that everything was down to smoking” [27, 28, p. 4].
Participants described undergoing a series of examina-
tions, referrals and misdiagnoses to find an explanation 
for their experiences.26–29 This process left participants 
feeling ‘frustrated’ [21, p. 103], ‘uncertain’ [26, p. 611], 
angry and “disillusioned” with the perceived meaning 
of their symptoms [28, p. 6]. Receiving the diagnosis 
was described as ‘life- changing’ [37, p. 4]. While people 
responded differently, for instance, expressing feelings 
of ‘relief’—as they can now receive treatment [22, p. 
3]—‘shock’ [30, p. 38], helplessness30 and confusion,26 a 
strong emotional response was evident.31 Following the 
diagnosis, individuals ruminated over the cause of their 
disease.27
Treatment
Participants discussed their reliance on specialist 
centres,6 21 which helped reduce feelings of uncertainty by 
answering questions and dispelling false narratives about 
PH: ‘it (the diagnosis) wasn’t as devastatingly unhopeful 
as first appeared’ [28, p. 7]. A disparity in care between 
services was described,6 specifically, between specialist 
centres and community services in terms of knowledge, 
treatments and approach to care.21 28 31 Many participants 
expressed the need for greater collaboration between 
services.6 21 26 27
Individuals often discussed how they felt their care 
could be improved, which included, regular checkups,24 
receiving more information,27 32 promoting shared deci-
sion making26 and holistic care33 and involving family 
members.27
Participants did not view medication as a “cure” [29, p. 
2], but rather to alleviate symptoms, improve health and 
Figure 1 Preferred Reporting Items for Systematic Reviews 
and Meta- Analyses diagram. PH, pulmonary hypertension.
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Table 3 Summary of studies
Study Country Aim N % female
Age (mean 
unless 
stated) and 
range Ethnicity
Years since 
diagnosis 
(mean unless 
stated) and 
range
WHO classification 
of PH described by 
authors
WHO 
functional 
class
Data collection and 
analysis
Alami et al26 France To explore adult’s 
experiences of PH 
and identify potential 
improvements in care
16 63 49
24–75
NR NR 75%=idiopathic PAH
25%=heritable PAH
I=0%
II=38%
III=50%
IV=12%
Semi- structured 
interviews; grounded 
theory
Armstrong et 
al28*
UK To investigate 
participant’s 
experiences of being 
diagnosed with PH
30 60 56.3
26–80
NR <1 to >10 Group 1 PAH (86%)
37%=idiopathic PAH
23%=connective tissue 
disease- associated PAH
17%=congenital heart 
disease- associated PAH
3%=portopulmonary 
hypertension
3%=heritable PAH
3%=drugs/toxins- 
associated PAH
Group 3 PH- lung disease 
(3%)
Group 4 CTEPH (4%)
NR (3%)
I=0%
II=30%
III=63%
IV=7%
Semi- structured 
interviews; thematic 
analysis
Carroll et al24 USA To understand the 
motivations of why 
patients with PH 
partake in randomised 
controlled trials
26 85 Median 56
25th 
percentile 41
75th 
percentile 61
65% white,
19% black, 
15% 
Hispanic
Median 5.5
25th percentile 4
75th percentile 
11
Group 1 PAH (85%)
50%=idiopathic PAH
23%=connective tissue- 
associated PAH
4%=heritable PAH
4%=congenital heart 
disease- associated PAH
4%=portopulmonary
Other/unknown 15%
I–III=100% Randomised 
participants to 
review a hypothetical 
randomised controlled 
trial that did or did 
not allow continuation 
of pre- existing PAH 
therapies followed 
by semi- structured 
interviews; thematic 
analysis
Chiang et al30 Taiwan To explore treatment 
experiences in 
individuals with PH
17 76 53.6
27–84
NR 6.4
2–15
Form of PH not specified NR Semi- structured 
interviews; thematic 
analysis
Continued
 on December 16, 2020 by guest. Protected by copyright. http://bmjopen.bmj.com/ BMJ Open: first published as 10.1136/bmjopen-2020-041428 on 7 December 2020. Downloaded from 
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Study Country Aim N % female
Age (mean 
unless 
stated) and 
range Ethnicity
Years since 
diagnosis 
(mean unless 
stated) and 
range
WHO classification 
of PH described by 
authors
WHO 
functional 
class
Data collection and 
analysis
Flattery et al20 USA To describe patients 
experiences of PAH 
and explore the 
impact
11 73 58.5
40–72
‘Most were 
white’ (p. 
101)
3.5
0.5–14
Group 1 PAH
55%=idiopathic PAH
18%=systemic 
lupus erythematosis- 
associated PAH
9%=mixed connective 
tissue disease
9%=portopulmonary 
hypertension;
9%=other PAH
Not specified (45%)
NR Semi- structured 
interviews; Colaizzi’s 
approach to 
phenomenological 
analysis
Goddard et al21 UK To use narrative 
analysis to explore the 
impact of PH
12 50 20–79 NR NR Group 1 PAH (100%) NR Unstructured narrative 
interview; narrative 
analysis
Hall et al31 Canada To describe patient’s 
experiences of 
adjusting to PH 
and continuous 
intravenous 
epoprostenol
7 71 55
43–70
NR 3
0.5–7
Group 1 PAH (100%) NR Semi- structured 
interviews; constant 
comparison method
Ivarsson, 
Ekmehag B27+
Sweden To describe patient’s 
experience of 
information provision 
in PH
17 76 56
28–73
NR 5
1–12
Group 1 PAH (71%)
35%=idiopathic PAH
24%=systemic sclerosis- 
associated PAH
12%=PAH
Group 4 CTEPH (29%)
11% treated 
by pulmonary 
endarterectomy
NR Semi- structured 
interviews; content 
analysis
Ivarsson, 
Ekmehag B34+
Sweden To describe patient’s 
experiences of 
support in PH
17 76 56
28–73
NR 5
1–12
Group 1 PAH (71%)
35%=idiopathic PAH
24%=systemic sclerosis- 
associated PAH
12%=PAH
Group 4 CTEPH (29%)
11% treated 
by pulmonary 
endarterectomy
NR Semi- structured 
interviews; content 
analysis
Keen et al6 UK To explore the nature 
of physiotherapy for 
PH in patients
3 67 44–66 NR 8–10 Pulmonary hypertension 
Breakdown of 
classification not 
specified
NR Semi- structured 
interviews; framework 
analysis
Table 3 Continued
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Study Country Aim N % female
Age (mean 
unless 
stated) and 
range Ethnicity
Years since 
diagnosis 
(mean unless 
stated) and 
range
WHO classification 
of PH described by 
authors
WHO 
functional 
class
Data collection and 
analysis
Kingman et al29 International 
study—
Europe, 
Asia, North 
America, 
South 
America
To examine patient’s 
perspectives of PH, 
including impact 
of living with PH, 
management and 
treatment
39 75 19–91 NR NR Group 1 PAH (87%)
Group 4 CTEPH (13%)
I=5%
II=36%
III=44%
IV=15%
Video of participants 
in their home, field 
notes and participant’s 
diaries; ethnography
Lee et al33 International 
study
To investigate different 
data sources to 
better understand 
perspectives of those 
with PH
1087 from 
online 
discussion 
board;
27 from 
archival 
data
NR NR NR NR Group 1 PAH (100%) NR Collected from online 
discussion boards 
and Food and Drug 
Administration archival 
data; NR
Lo et al17ˆ Canada To examine the 
presentation of 
existential distress in 
those with PAH
30 77 52
24–77
57% white,
20% South 
Asian, 3% 
black, 3% 
Arab, 3% 
Indigenous, 
13% other
6.3
0.5–24
Group 1 PAH (93%)
40% PAH associated 
with CTD
Group 2 PH left heart 
disease (7%)
I=10%
II=60%
III=23%
IV=7%
Semi- structured 
interview; thematic 
analysis
Matura et al35 International 
study
To examine how 
people with PH 
are using online 
discussion boards
549
data 
available 
for n=155
92 45.6
19–78
NR NR Form of PH not 
specified but n=95 used 
prostanoid therapy, 
which is approved for 
group 1 PAH
Participants 
who self- 
identified 
with PH 
group 
I–V were 
included
Data were collected 
from online discussion 
board posted by 
individuals with PH; 
qualitative descriptive 
methodology
Martin et al37ˆ Canada To identify avoidant 
techniques in patients 
with PH when 
discussing difficult 
topics associated with 
the disease
30 77 52
24–77
57% white 6.3
0.5–24
Group 1 PAH (100%)
40% PAH associated 
with connective tissue 
disease
II=60% Semi- structured 
interview; qualitative 
content analysis
McDonough, 
Matura LA23
USA To explore symptoms 
and their impact on 
participants with PH 
experience
10 70 65
38–81
80% white
10% Asian- 
American
10% other
5.3
1–10
Group 1 PAH (100%) I=10%
II=10%
III=70%
IV=10%
Semi- structured 
interviews; qualitative 
descriptive 
methodology
Table 3 Continued
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Study Country Aim N % female
Age (mean 
unless 
stated) and 
range Ethnicity
Years since 
diagnosis 
(mean unless 
stated) and 
range
WHO classification 
of PH described by 
authors
WHO 
functional 
class
Data collection and 
analysis
Muntingh et 
al25
The 
Netherlands
To explore mental 
health needs in 
patients with PH
24 83 26–69 NR 0–16 Group 1 PAH (100%) NR Semi- structured 
interviews; mixed 
methods—constant 
comparison method
Uhlenbusch, 
Löwe B 
(2019)32
Germany To explore burden 
of living with a rare 
disease, including PH
4 NR NR NR NR Group 1 PAH (100%) NR Focus groups; content 
analysis
Yorke J, 
Armstrong I36*
UK To explore 
participant’s 
experiences of daily 
life with PH
30 60 56.3
26–80
NR <1 to >10 Group 1 PAH (89%)
37%=idiopathic PAH
23%=connective tissue 
disease- associated PAH
17%=congenital heart 
disease- associated PAH
3%=heritable PAH
3%=portopulmoary 
hypertension
3%=drugs/toxins- 
associated PAH
Group 3 PH- lung (3%)
Group 4 CTEPH (7%)
NR 3%
I=0%
II=30%
III=63%
IV=7%
Semi- structured 
interviews; thematic 
analysis
*, +, ˆ same sample investigated across studies.
CTEPH, Chronic thromboembolic pulmonary hypertension; n, number; NR, not reported; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension.;
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ultimately, survival: “[if medication was stopped] Well, all 
of us would die. It’s as simple as that” [25, 27, 29, 31–33, 38, 
p. 458]. Many reported an almost immediate reduction 
in symptoms attributed to treatment,27 34 with a ‘strong 
emotional attachment’ to medication being noted [25, 33, 
p. 5].
Side effects of treatments were common, which seemed 
to mostly manifest physically.20 23 32 There was uncer-
tainty surrounding side effects as participants reflected 
that it was not always clear whether their symptoms were 
associated with the disease itself or psychosocial burden 
of PH.33 35 Side effects posed as a barrier to adherence, 
as while some viewed the negatives of treatment as a 
tradeoff: “it’s added years to my life…but it’s bittersweet” [21, 
p. 102], others stopped despite the risk.36
Other barriers were discussed such as, accessibility and 
cost of treatment, emotional distress and problems with 
self- administration.23 24 31–34 36 Lack of perceived need also 
affected uptake as while many experienced emotional 
difficulties, some felt they did not need psychological 
support,34 perceiving: “the disease itself is the problem”[29, 
p. 4]. However, some expressed the need for help with 
managing anxiety and low mood.25
Participants described a number of worries associated 
with their treatment, such as, whether it was effective20 
and if so for how long,36 potential risks,31 what other 
options are available29 31 36 and the wait to receive treat-
ment.17 Visible treatments could be a source of ‘social 
stigma’ [27, 38, p. 456], leaving participants feeling ‘self- 
conscious’ [33, p. 4].
Prognosis
Participants were saddened,30 “terrified”[35, p. 162] and 
anxious over the prospect of their death.17 25 Individuals 
described many uncertainties associated with their prog-
nosis including, how their disease would progress,23 35 
what their future would hold,34 the impact of their death 
on loved ones17 21 25 and how long they had remaining: “I 
am clueless as to how long my heart will hold out” [29, p. 3]. 
One women wondered if her death would make it “easier” 
due to the impact of PH on her family [17, p. 4]. The 
pervasive fear over when or how their symptoms would 
worsen ‘plagued’ participants [24, p. 129], resulting in 
emotional and psychological difficulties.23 34
Healthcare professionals
Developing a therapeutic relationship with a PH “expert” 
was important [33, p. 5]. Professionals were described as a 
source of support,34 advice,6 knowledge,31 reassurance,28 
motivation and ‘hope’ [29, 31, p. 4]. That said, participants 
Table 4 Quality assessment using critical appraisal skills programme18
Study
Criteria
Rating1 2 3 4 5 6 7 8 9 10
Alami et al26 + + + + + + + + + + ++
Armstrong et al28* + + + + + – + + + + ++
Carroll et al24 + + – + + – + + + + ++
Chiang et al30 + + – + + – + + + + +
Flattery et al20 + + + + + – + + + + +
Goddard et al21 + + + + + – + + + + ++
Hall et al31 + + + + + + + + + + ++
Ivarsson B, Ekmehag B27+ + + – + + – + + + + +
Ivarsson B, Ekmehag B34+ + + – + + – + + + + +
Keen et al6 + + – – – – + + + + –
Kingman et al29 + + + + + – + + + + ++
Lee et al33 + + + + + – + – + + +
Lo et al17ˆ + + – + + – + + + + +
Matura et al35 + + + + + + + + + + ++
Martin et al37ˆ + + – + – – + + + + +
McDonough A, Matura LA23 + + + + + + + + + + +
Muntingh et al25 + + + + + – + + + + ++
Uhlenbusch N, Löwe B32 + + + + + – + + + + ++
Yorke J, Armstrong I36* + + + + + – + + + + ++
*, +, ˆ same sample investigated across studies.
Was the research aim(s) (1) clearly stated and (2, 3) addressed using a qualitative approach. Evaluation of the: (4) recruitment strategy, (5) data 
collection method, (6) issues concerning reflexivity, (7) ethical implications, (8) data analysis, (9) clarity of findings and (10) overall value of the 
research.
 o
n
 D
e
c
e
m
b
e
r 1
6
, 2
0
2
0
 b
y
 g
u
e
s
t. P
ro
te
c
te
d
 b
y
 c
o
p
y
rig
h
t.
h
ttp
://b
m
jo
p
e
n
.b
m
j.c
o
m
/
B
M
J
 O
p
e
n
: firs
t p
u
b
lis
h
e
d
 a
s
 1
0
.1
1
3
6
/b
m
jo
p
e
n
-2
0
2
0
-0
4
1
4
2
8
 o
n
 7
 D
e
c
e
m
b
e
r 2
0
2
0
. D
o
w
n
lo
a
d
e
d
 fro
m
 
9Rawlings GH, et al. BMJ Open 2020;10:e041428. doi:10.1136/bmjopen-2020-041428
Open access
reported some difficulties accessing or discussing their 
worries with professionals,26 27 as well as previous encoun-
ters in which professionals lacked competency,32 empathy 
or sensitivity: one participant, for example, reported 
being told “It’s [PH] worse than cancer, we can’t treat it” [28, 
p. 3].
Participants expressed their frustration over health-
care professionals’ poor understanding of PH.28 31 32 Indi-
viduals spoke of pleading or taking it on themselves to 
explain the disease to staff.21 27
Impact
A range of symptoms were experienced by participants 
including, dyspnoea, pain, dizziness, fatigue, palpitations 
and cognitive difficulties.20 21 23 26 32 35 Breathing prob-
lems, however, were described as the “main symptom” [27, 
p. E16], which was associated with feelings of breathless-
ness, ‘suffocating’, ‘choking’ and ‘pain’—this was closely 
interlinked with anxiety [24, 27, p. E16]. Breathing 
could become a ‘conscious act’ [27, p. E16], as participants 
provided precise details over which activities would cause 
them shortness of breath [27, p. E17]. That said, some 
symptoms were ‘unpredictable’ and likened to being on a 
‘rollercoaster’ [30, 38, p. 456].
Decline in physical ability, mobility and energy levels 
were prevalent,25 30 which could be caused by any form of 
activity.23 26 31 Participated expressed ‘fear’ of engaging in 
activities [33, p. 4] due to the onset of symptoms, pain23 
or it requiring too much energy.34 There seemed to be a 
discrepancy between participant’s ideal and actual self, in 
terms of ability,26 which manifested in feelings of ‘anger’ 
[24, p. 129], ”failing” [22, p. 4], ‘disappointment’ [32, p. 38] 
and shame.34
Individuals had to reduce or cease many activities,17 26 37 
leading them to relate their situation to a “shackle” [33, 
p. 4]. Reflected in this, was the feeling of restriction, the 
nature of which had a considerable impact on profession, 
family and social roles.17 21 25 26 30 32 33 This appeared to 
be, somewhat, moderated by age, gender and stage of the 
disease.17 25 For example, younger participants had to limit 
themselves to activities that matched their ‘activity toler-
ance’ opposed to interests [33, p. 4]. Participants reported 
sexual difficulties largely due to fatigue and shortness of 
breath, which negatively affected their relationship.17 26 34 
Financial problems associated with the cost of care and 
loss of earnings.25 30 32 Practical and emotional problems 
caused by travelling.31 34 Male and female participants 
discussed difficulties associated with having or caring for 
their children.17 21 25 27 34
There was a general sense that the disease could be 
invisible and “hidden” from others [38, p. 456]. Family, 
friends, the public, local authorities, insurance compa-
nies and even healthcare professionals were all described, 
at times, as failing to understand the disease and partic-
ipant’s physical limitations.17 20 26 27 32 34 36 Participants 
found themselves having to ‘battle’ for their illness to be 
recognised [38, p. 458], and justify their difficulties.27 34
Life with PH could have a negative effect on partic-
ipant’s mental health, with anxiety, low mood, isola-
tion23 25 29 32 35 and suicidal ideation being discussed.30 37
Coping
Participants required a period of time to adjust to life with 
PH.20 23 30 36 Individuals coped differently, for example, 
an international study observed two approaches: ‘disease 
dominated’ whereby participants harboured a ‘passive atti-
tude towards PH’, were dependent on others, and likely 
to experience depression; whereas ‘solution seekers’ devel-
oped strategies to manage, were less dependent and 
maintained a social life [33, p. 4].
A common approach to coping was preparation,21 
‘extensive planning’ and developing ‘daily routines’ [30, 
33, p. 5]. Individuals discussed weighing up how activi-
ties would impact them, rather than “act on impulse” [24, 
p. 127]. Participants reported feeling like they had to 
‘hold back or take it [daily activities] slow’ [21, 24, p. 127]. 
Personal limits were learnt through ‘testing’ their own 
ability [30, p. 39].
Many acknowledged the importance of developing a 
helpful or positive “mindset” [26, 29, p. 4], for example, 
focusing on activities that were still within their ability23: 
“I tell myself that I have to look at what I can still do…” [30, 
p. 39]. Self- talk,31 focusing on having overcome previous 
adversity,37 faith20 and self- humour were also used to 
cope.20 21
Altering expectations of ability, recovery and 
future25–27 36 allowed some to develop a new sense of 
purpose31 or “redefine’”their lives [24, p. 128, 27, 35]. 
Accepting their limits gave participants the perception 
that they were not letting their disease “dominate” [25, 
26, 33, p. 4] and provided a sense of control23: “…it’s 
just my life, it’s just what I do” [21, p. 102]. Keeping active 
was described as helping to shift their focus away from 
their symptoms,35 control disease progression and have 
psychological benefits.6
Family, friends and employers were described as 
offering practical and emotional support.25 29 30 34 35 
However, participants appeared conflicted, describing 
their own position as “enforced dependency” [17, 33, p. 3]. 
Social support could also be a barrier or counterproduc-
tive to coping, as how others dealt with the disease was not 
always helpful.32 34
Participants spoke about concealing, avoiding, dimin-
ishing and making excuses for their difficulties.17 21 29 30 36 37 
This helped reduce some of the emotional impact of PH, 
as well as feeling less of a burden or protecting others.31 34 37 
However, this could lead to social withdrawal and isola-
tion, further straining relationships and causing psycho-
logical difficulties.25 29 30
Peer supports groups and organisations were common 
sources of reassurance, support and advice.32 34 Individ-
uals sought validation and normalisation of their symp-
toms from people with shared experience35 and also 
looked to help others.24
 o
n
 D
e
c
e
m
b
e
r 1
6
, 2
0
2
0
 b
y
 g
u
e
s
t. P
ro
te
c
te
d
 b
y
 c
o
p
y
rig
h
t.
h
ttp
://b
m
jo
p
e
n
.b
m
j.c
o
m
/
B
M
J
 O
p
e
n
: firs
t p
u
b
lis
h
e
d
 a
s
 1
0
.1
1
3
6
/b
m
jo
p
e
n
-2
0
2
0
-0
4
1
4
2
8
 o
n
 7
 D
e
c
e
m
b
e
r 2
0
2
0
. D
o
w
n
lo
a
d
e
d
 fro
m
 
10 Rawlings GH, et al. BMJ Open 2020;10:e041428. doi:10.1136/bmjopen-2020-041428
Open access 
Analytical themes
Four key analytical themes emerged:
Managing uncertainty
Participants acknowledged many uncertainties caused 
by internal, such as bodily sensations, or external events 
linked to PH, including the reaction of others26 or what 
the future may hold.17 Uncertainty was often associated 
with a perception of risk or threat, which precipitated 
and perpetuated psychological, emotional and physio-
logical distress. Many of the approaches that participants 
employed to manage their difficulties related to uncer-
tainty seemed to only provide brief relief, until the next 
unknown situation occurred, or their strategy fed back 
into their level of distress, for example:
Participants sought information and reassurance from 
a range of sources,20 in the hope of gaining knowledge, 
understanding and some sense of certainty.28 Unfortu-
nately, given the complexity and lack of understanding of 
PH, this could result in even greater uncertainty.28
Individuals seemed to engage in worry as a helpful 
means to problem solve, plan and minimise negative 
outcomes. However, planning could be impractical due 
to the unpredictable nature of PH36 or it removed ‘spon-
taneity in their life’ [24, p. 127]. Worrying was also closely 
linked with hypervigilance to the impact of everyday 
activities23 and somatic changes as an ‘indicator’ to alter 
behaviour [22, 27, p. E17]. This resulted in anticipatory 
anxiety and panic.23
Some described avoiding25 37 or concealing their 
disease, however, this often prolonged distress and 
resulted in emotional difficulties, such as anxiety, guilt 
and loneliness.17
Physical nature of PH
PH was described as a physically limiting disease,32 as 
was there a tendency for individuals to report somatic 
experiences.21 23 26 Furthermore, despite experiencing 
emotional difficulties, participants often resisted the idea 
or need for psychological support.25 32 37 A notion further 
reflected in the relief on hearing the disease was not 
psychosomatic in nature.28
Conversely, participant’s social environment did not 
always recognise the physical manifestations of the 
disease—participants assumed because “you can’t see 
anything” and most of the time they “look fine” as there 
was a lack of visible signs [26, 38, p. 455]. Discordance 
between the meaning and impact participants and others 
attached to the disease seemed most salient on occasions 
when physical adaptations were required due to fatigue 
or breathlessness—symptoms of which could be invisible 
to others.25 34 It seemed the support participant’s received 
was, at times, influenced by other’s representation of 
the disease.21 Likewise, participant’s own perceptions of 
their circumstance may have affected their experiences of 
coping, which could help, in part, to explain resistance to 
psychological support.
Living with the rarity of PH
The rarity of PH was highlighted in discussions,25 26 no 
more so than when individuals expressed their frustra-
tion at the lack of PH awareness in society and health-
care.27 32 Lack of understanding and misconceptions 
over PH resulted in participants feeling stigmatised and 
discriminated against.21 25 32 Participants found themselves 
having to justify and legitimise their sick role, despite 
having an incurable disease32 36 or withdrawing to avoid 
difficulties.17 Individuals felt the need to become experts 
in PH, which made it all the more frustrating when others 
assumed that they knew better or when participant’s 
voices were unheard in care.21 27 Living with a rare condi-
tion left individuals feeling lonely and isolated: “forced to 
carry a burden no one wants, or understands fully” [33, p. 4]. 
Participants found understanding from experts in PH 
and PH communities.20
Transitional nature of PH
Participants progressed through different transitions 
living with PH.25 At first, experiencing a decline in general 
functioning, which appeared to improve following the 
diagnosis and administration of treatment.28 Partici-
pants next faced the process of adapting to life with PH 
and treatment,20 31 the goal of which was to stabilise the 
disease,6 maintain a good QoL and survive.25 Participants 
had to find a balance between feeling underactive, in 
which they perceived their identity as changing17 and 
themselves “failing” [22, p. 4], and overactive, whereby 
participants attempted to resume normal life despite the 
risk and increase in PH symptoms, or dissonance feeling 
torn between societal norms and their own ability.23 This 
balance was often achieved through ‘trial and error’ [30, p. 
39] and becoming more aware of physical, psychological, 
family and society cues.
DISCUSSION
This review presents the first systematic synthesis of qual-
itative data exploring adults’ experiences of living with 
PH. Four analytical themes emerged reflecting: how indi-
viduals navigate uncertainty associated with PH; the phys-
ical and somatic nature of PH; implications of living with 
a rare disease and the transitional nature of adapting to 
life with PH.
Feelings of uncertainty are commonly experienced by 
individuals with a rare medical condition.38 For partici-
pants in the current review, uncertain events were often 
perceived as threatening resulting in distress. Intoler-
ance to uncertainty is one of the main theories aimed at 
understanding generalised anxiety disorder (GAD).39 In 
GAD, individuals find the feeling of uncertainty difficult. 
This distress is often managed by engaging in worry as a 
method to prepare for possible eventualities. The associ-
ated anxiety however influences individuals to appraise 
and overestimate events as negative and threatening. As 
observed here, this can generate greater uncertainty and 
anxiety.39 40 A study investigating GAD in PH found 93% 
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reported some symptoms.41 Symptoms of GAD in PH has 
been found to be associated with depression,41 which may 
impact patient’s ability to adapt to the challenges of PH.42 
Although anxiety and depression in PH is common, just 
over one- third of patients receive treatment.43 Strategies 
aimed at helping individuals to better manage distress 
associated with uncertainty are likely to be useful. A 
range of psychological treatments have been shown to be 
effective for GAD,44 however, there is paucity of evidence 
regarding psychological treatments in PH.45
Participants focused primarily on the physical diffi-
culties of PH. While this may indeed be how the disease 
presents, individuals described becoming more aware of 
somatic feedback to help gauge their own body. Individ-
uals investigated elsewhere who experienced chest pain 
have also reported hypervigilance to cardiopulmonary 
sensations. The degree of vigilance was positively related 
to chest pain, the association of which was mediated by 
fear of bodily sensations.46 A similar relationship can be 
observed in Clark’s model of panic, whereby perceptions 
of threat and anxiety over somatic symptoms increase the 
likelihood of experiencing, and also misinterpreting, a 
bodily sensation as negative.47 Individuals with PH should 
be supported to better understand and differentiate the 
shared overlap between cardiovascular symptoms and 
anxiety.48 Interventions, such as mindfulness, that help 
individuals disengage their attention from sensations may 
also be beneficial.49
Disparity in illness perceptions between participants 
and others was a common source of distress. This has also 
been reported in other diagnoses that are associated with 
poor understanding and uncertainty.50 Such incongru-
ences have been suggested to influence how individuals 
present to services with their symptoms and adherence to 
treatment.51 Healthcare professionals may benefit from 
additional training on PH, as well as developing skills to 
help explore individual’s understanding of the disease, 
and perceived psychosocial impact.52 While greater 
consideration of individual’s social support in PH care 
will likely minimise the impact and degree of conflicting 
perceptions, helping patients to develop skills to manage 
conversations when other people are confused about PH 
is also important.53
PH care should reflect the transitional nature involved 
in adapting to life with PH. This may help to minimise 
or prevent worsening of psychosocial symptoms following 
their PH diagnosis.54 Initially, individuals are likely to 
value from additional support in understanding PH, 
managing the emotional impact of the diagnosis and 
integrating the disease into their identities exploring 
existential worries. For example, caregivers should help 
individuals to explore their difficulties and construct new 
meaning.55 Experiences of fatigue appeared a prominent 
theme thereafter as individuals aimed to find a balance 
between their energy and engaging in activities. Fatigue 
is the second most common symptom patients with PH 
present with.52 Supporting individuals to manage fatigue 
through education, pacing and prioritising valued 
actions is likely to helpful—this may also reduce mood 
disorders.56
Limitations
Most studies did not discuss reflexivity. This involves the 
researcher attending to the wider content of knowledge 
acquisition, discussing the potential role of relationships 
between participants and themselves in their investi-
gation.57 This is an important stage in some qualitative 
research approaches and also contributes to rigour and 
trustworthiness.58
Due to lack of reporting, the analysis was unable to 
distinguish between experiences based on PH- related 
factors, which has been shown to be associated with 
psychological distress.59 60 Grouping individuals based 
solely on their diagnosis of PH may have resulted in idio-
syncratic findings being missed. Moreover, experiences 
relating to palliative care, pregnancy, surgery and psycho-
logical interventions were largely unrepresented despite 
being commonly encountered in practice.
Finally, the review protocol has been registered on 
Open Science Framework registries; while it was not regis-
tered prior to data extraction, authors confirm that the 
protocol had not been altered since it was initially devised 
and prior to data extraction.
CONCLUSION
This review uniquely thematically synthesises qualita-
tive data from over 1900 individuals with PH across four 
continents, with the majority of participants recruited in 
two international studies.33 35 The review finds numerous 
voices are missing, which needs addressing, including 
those from palliative care, non- white background and 
individuals who have experienced pregnancy in PH. The 
results have implications for clinical practice highlighting 
the potential role of education and psychological thera-
pies to support those with the disease.
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